Preclinical Drug Equipment & Supplies
15 equipment items found
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso3 is a preclinical drug development program aimed at treating asthma. Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Investigate mechanisms of toxicity for preclinical drug candidates to help decrease clinical trial safety failures. Drug-induced liver injury (DILI) is a primary concern during drug development that remains poorly understood due to species differences in liver toxicity and the limited predictivity of conventional in vitro models. ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
Discovery and preclinical development of peptide drug candidates have been 3BP’s core competencies since the company’s inception. ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partnered drug candidate, ADX71149 is a novel orally active mGlu2 PAM for the treatment of epilepsy. Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. We expect the first part to be completed in the first quarter of 2023. ...
by:Sword Diagnostics, Inc. based inCarmel, INDIANA (USA)
Utilizing our proprietary Sword Swift™ Method Development Process and Sword Swift™ Detection Reagents, our scientists can develop sensitive quantitative assays to measure the amounts of free or bound drug in preclinical or clinical samples with high accuracy and ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody ...
Manufactured by:Bmseed based inMesa, ARIZONA (USA)
Mechanics Module: strain rate up to 1/s, strain up to 20%. Imaging Module: frame rate: 150fps. Electrophysiology Module: 2x60 channels. Physiological stretch of cells to reproduce the environment of cells inside the body; assessment of cell health, function, and maturity using electrophysiological measurements; visualization of cells and cellular processes during ...
Manufactured by:SiO2 Materials Science based inAuburn, ALASKA (USA)
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Evaluate drug candidate toxicity at clinically relevant concentrations in a co-culture human kidney model. Predicting drug-induced kidney toxicity and drug-drug interactions continues to be a challenge due to a reliance on immortalized cell line culture or animal models that do not translate to human response. The co-culture ...
Manufactured by:SiO2 Materials Science based inAuburn, ALASKA (USA)
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
Manufactured by:Ncardia Services B.V. based inLeiden, NETHERLANDS
The discovery that transformed biological research. In 2007, Shinya Yamanaka and Kazutoshi Takahashi were able to reprogram human somatic cells into pluripotent stem cells by inducing the expression of four embryonic transcription factors. The resultant cells were called human induced pluripotent stem cells (iPSC). iPSCs have unlimited proliferation capacity and can be differentiated into nearly ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Flu – A Serious, Deadly Disease with Pandemic Potential. In 1918, the Spanish flu (H1N1 influenza virus) rapidly killed 50 to 100 million people worldwide, affecting one of every five Americans. Today, influenza remains a common and serious respiratory illness that contributes to the reduction of quality of life and results in a significant loss of manpower hours each year. Every year, 40 ...
Manufactured by:InMed Pharmaceuticals Inc. based inVancouver, BRITISH COLUMBIA (CANADA)
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic ...